Summit Therapeutics (NASDAQ:SMMT) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday. A number of other equities analysts have also weighed in on the company. The Goldman Sachs Group boosted their target price on Summit Therapeutics from $37.00 […]
Wall Street Zen downgraded shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday. A number of other equities analysts have also weighed in on the company. The Goldman Sachs Group boosted their target price on Summit Therapeutics from $37.00 […]
